Poultry Medicine/Pharmaceuticals Market

The poultry medicine/pharmaceuticals Market is projected to reach USD  6.68 billion by 2029 from USD 5.01 billion in 2024, at a CAGR of 5.9 % from 2024  to 2029. The poultry medicine/pharmaceuticals market has performed gallantly over the years owing to the increase in the consumption of poultry products, the growth of poultry industries, and the improvement of animal health and food safety. Such development is reinforced by the innovations seen in the vaccines and antibiotics and the development probiotics which aim at poultry diseases.

The prominent players in the poultry medicine/pharmaceuticals market are MSD (US), Elanco (US), Boehringer Ingelheim (Germany), Ceva Sante Animale (France), Zoetis Service LLC (US), Virbac (France), Phibro Animal Health (US).

To know about the assumptions considered for the study download the pdf brochure

MSD (US)

MSD Animal Health is one of the top companies in the global animal health sector and an important player in the market of poultry pharmaceuticals. With extensive range of products devoted to poultry health, MSD has made inroads in developed markets with vaccines, novel drug delivery systems, and sophisticated disease prevention and treatment modalities. The company’s main objective is improving productivity and animal health, more specifically for the poultry industry the problems of infectious agents, respiratory problems, and growth promotion.

ELANCO (US)

Elanco Animal Health, a global leader in animal health, has established a significant market share in poultry medicine/pharmaceuticals. Elanco’s approach to poultry medicine/pharmaceuticals has allowed it to create a variety of necessary solutions to the critical health needs in poultry farming ranging from infectious diseases to parasite management. The product portfolio of the world leader, it includes antibiotics, vaccines, anticoccidials, parasiticides, nutritional health and other solutions. The product is well accepted in the markets globally and especially in the Americas, Europe and Asia pacific regions. R&D becomes one of the major driver of such growth and new strategies within the company focus on partnering with universities and other biotech companies to enhance the company’s pipeline of products.

BOEHRINGER INGELHEIM (GERMANY)

Boehringer Ingelheim, located in Germany, is one of the major players globally in animal medicines, specifically in the poultry division engaged in the enhancement of poultry health with the help of vaccines, therapeutics, and biosecurity measures. Boehringer Ingelheim’s unyielding focus on R&D is to enhance the Company’s product pipeline especially towards vaccine development and non-antibiotic treatments. In addition, the company has a solid presence across the globe enabling it to operate in different regulatory regimes without any challenges. All these strengths in addition to sustainability and provision of extension services to the farmers enable Boehringer Ingelheim to dominate the global poultry medicine/pharmaceutical market, which has current and future promises of healthy and sustainable poultry production.

Related Reports:

Poultry Medicine/Pharmaceuticals Market by Animal Type (Chickens, Turkeys, Ducks), Product (Drugs, Vaccines, Feed Additives), Disease Indication (Newcastle disease, Infectious Bursal Disease, Salmonella), Route of Administration - Global Forecast to 2029

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com